11 results on '"Burhanullah, Haroon"'
Search Results
2. Rural Healthcare Workers' Well-Being: A Systematic Review of Support Interventions
- Author
-
Malik, Mansoor, primary, Penalosa, Martina, additional, Busch, Isolde Martina, additional, Burhanullah, Haroon, additional, Weston, Christine, additional, Weeks, Kristina, additional, Connors, Cheryl, additional, Michtalik, Henry J., additional, Everly, George, additional, and Wu, Albert W., additional
- Published
- 2023
- Full Text
- View/download PDF
3. To the Editor: COVID-19 as a Catalyst to Transform Graduate Medical Education
- Author
-
Malik, Mansoor, primary, Gandhi, Sonal, additional, Gupta, Ishaan, additional, Burhanullah, Haroon, additional, Michtalik, Henry, additional, Eid, Shaker, additional, and Van Wert, Michael, additional
- Published
- 2022
- Full Text
- View/download PDF
4. Pilot Trial of Dronabinol Adjunctive Treatment of Agitation in Alzheimer's Disease (THC-AD)
- Author
-
Outen, John, Rosenberg, Paul, Vandrey, Ryan, Amjad, Halima, Burhanullah, Haroon, Agronin, Marc, Castaneda, Ricardo, Isesalaya, Maria, Walsh, Patricia, Ash, Eleanor, Cohen, Leah, Wilkins, James, Harper, David, and Forester, Brent
- Published
- 2021
- Full Text
- View/download PDF
5. Pilot trial of dronabinol adjunctive treatment of agitation in Alzheimer's disease (THC‐AD)
- Author
-
Rosenberg, Paul B., primary, Outen, John D., additional, Amjad, Halima, additional, Burhanullah, Haroon, additional, Vandrey, Ryan, additional, Agronin, Marc, additional, Castaneda, Ricardo, additional, Isesalaya, Maria, additional, Walsh, Patricia, additional, Ash, Eleanor T., additional, Cohen, Leah, additional, Wilkins, James M, additional, Harper, David G., additional, and Forester, Brent P., additional
- Published
- 2021
- Full Text
- View/download PDF
6. Psychological First Aid Well-Being Support Rounds for Frontline Healthcare Workers During COVID-19
- Author
-
Malik, Mansoor, primary, Peirce, Jessica, additional, Wert, Michael Van, additional, Wood, Cynthia, additional, Burhanullah, Haroon, additional, and Swartz, Karen, additional
- Published
- 2021
- Full Text
- View/download PDF
7. TRIAL OF DRONABINOL ADJUNCTIVE TREATMENT OF AGITATION IN ALZHEIMER'S DISEASE (AD) (THC-AD)
- Author
-
Rosenberg, Paul, primary, Forester, Brent, additional, Agronin, Marc, additional, Kasckow, John, additional, Amjad, Halima, additional, Burhanullah, Haroon, additional, Vandrey, Ryan, additional, Outen, John, additional, Skurla, Miranda, additional, May, Rose, additional, and Isesalaya, Maria, additional
- Published
- 2020
- Full Text
- View/download PDF
8. Pilot trial of Dronabinol adjunctive treatment of agitation in Alzheimer's disease (THC‐AD).
- Author
-
Rosenberg, Paul B., Outen, John D., Amjad, Halima, Burhanullah, Haroon, Vandrey, Ryan, Nowrangi, Milap A., Schultz, Meghan, Isesalaya, Maria, Castaneda, Ricardo, Agronin, Marc, Walsh, Patricia, Drury, Mia, Ozonsi, Rosain, Cohen, Leah, Wilkins, James M., Harper, David G., and Forester, Brent P.
- Abstract
Background: Agitation in Alzheimer's Disease (Agit‐AD) is a common and troubling neuropsychiatric syndrome which adds significantly to disability and caregiver stress. Behavioral interventions lack consistent efficacy and there are no FDA‐approved medications. Neurobiological mechanisms that contribute to Agit‐AD include brain atrophy, degradation of neurotransmission, neuroinflammation, disrupted circadian rhythms, comorbidities and frailty. Agit‐AD is a major source of disease progression, patient disability, financial burden, and caregiver stress. Dronabinol is a synthetic cannabinoid (tetrahydrocannabinol, THC). Cannabinoids may improve Agit‐AD by providing protection against neuroinflammation and excitotoxicity, regulating neurotransmitters, improving comorbidities, stabilizing circadian rhythms, and increasing cerebral blood flow. Method: THC‐AD is a three‐week placebo‐controlled, double‐blind, RCT of dronabinol (10 mg QD) in 80 patients with severe Agit‐AD. Twice daily administration maximizes daytime coverage for agitation and minimizes sundowning. Inclusionary criteria include a diagnosis of AD, severe agitation, and being 60‐95 years old, while exclusionary criteria include serious or unstable medical illness, seizure disorder, delirium, current use of lithium, and inability to swallow a pill. Primary outcomes include a change in the Pittsburgh Agitation Scale and NPI‐C Agitation/Aggression subscales. Result: We have enrolled 58 out of targeted 80 participants (Table 1: mean age 77.8 years, 65.5% female, 87.9% Caucasian, mean education 13.8 years, 45.6% family history). On average, study participants are very cognitively impaired (Table 2: mean baseline MMSE of 8.1), very agitated (mean NPI‐C Agitation 14.6, mean NPI‐C Aggression 6.3) and in reasonable overall health (Figure 1: General Medical Health Rating, 12.1% "excellent," 51.7% "good" and 34.5% "fair"). Recorded AEs have been tolerable (Figure 2). Due to the COVID‐19 pandemic, we expanded our inpatient trial to include outpatient enrollments and implemented hybrid visits with telemedicine to limit in‐person interactions. We also added a supplemental study to evaluate the effects of the pandemic on caregiver stress and burden. We are collaborating with additional clinical sites, increasing dementia bed capacity, and deploying recruitment strategies for outpatients, including referrals from providers and other research trials, social media ads, and virtual community outreach. Conclusion: Safe and effective interventions for severe agitation are greatly needed. This pilot trial will help to examine the safety and efficacy of dronabinol for Agit‐AD. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): study protocol for a randomized controlled trial
- Author
-
Scherer, Roberta W., Drye, Lea, Lerner, Alan J., Gallagher, Damien, Dinoff, Adam, Vieira, Danielle, Bray, Jennifer, Abraham, Eleenor, Craft, Suzanne, Jenkins, Alecia, Dahl, Deborah, Rogers, Samantha, Sachs, Bonnie, Levey, Allan, Mann, Emily, Shaw, Edward, Sink, Kaycee, Caulder, Erin, Jefferson, Magie, Martin, Camilla, Shore, Kelsey, van Dyck, Christopher H., Kemp, Emily, Michalak, Hannah, Porsteinsson, Anton, Becker, Melinda, Pugh, Erika, Godek, Tyler, MacAvoy, Martha, Good, Susan, Ebner, Megan, McDonald, Julia, Ramanan, Srinath, Mecca, Adam, Lu, Oliver, ADMET 2 Research Group, Mintzer, Jacobo, Clark, David, Battjes-Siler, Debra, Smith, Stan, O'Neil, Courtney, Stocking, Nicole, Perin, Jamie, Shade, David, Jones, Jennifer, Holland, Stephanie, Wentz, Alicia, Chattopadhyay, Shumon, Grove, Bethany, Lanctôt, Krista, Herrera, Stephanie, Kaiser, Kristen, Lears, Andie, Broadnax, April, Mohammed, Aisha, Ryan, Laurie, McKelvy, Alvin, Elliott, Cerise, Rockwood, Kenneth, Edland, Steve, Rosenberg, Paul, Turner, Raymond Scott, Padala, Prasad, Hodges, Debbie, Jackson, Nicole, Padala, Kalpana, Burke, William, Batchuluun, Dawn, Burke, Anna, Grigaitis-Reyes, Michele, DiLise-Russo, Marjoire, Herrmann, Nathan, Vadovicky, Shelia, Favaro, Susan, Hernandez, Mary Lou, Autry, Lynn, Hoffmann, Nicole, Sanback, Rebecca, Lujan, Lazaro Martinez, Young, Elena, Lerner, Alan, Sami, Susie, Sanders, Marianne, Fatica, Parianne, Gross, Maria, Gore, Ethan, Mahajan, Supriya, Lah, James, Attis, Tamara, Cellar, Janet, Hales, Chad, Brawman-Mintzer, Olga, Walker, Margaret, Peterson-Hazan, Susan, Bolles, Erin, Carter, Erin, Marano, Chris, Dixon, Jasmine, Lawrence, Sarah, Schulz, Meghan, Burhanullah, Haroon, Salem-Spencer, Susan, Martin, Kim, Rice, Audrey, Kowalski, Nancy, Cervello, Michelle, Keltz, Melanie, Lane, Kaitlyn, Widman, Asa, Awkar, Anthony, O'Connell, Abigail, Williams, Arthur, Howland, Sheila, Hails, Alex, Orwat, Dennis, and Li, Abby
- Subjects
medicine.medical_specialty ,Time Factors ,Apathy ,Medicine (miscellaneous) ,Placebo ,law.invention ,03 medical and health sciences ,Study Protocol ,0302 clinical medicine ,Quality of life ,Randomized controlled trial ,law ,Alzheimer Disease ,medicine ,Dementia ,Humans ,Multicenter Studies as Topic ,Pharmacology (medical) ,Psychiatry ,Randomized Controlled Trials as Topic ,lcsh:R5-920 ,030214 geriatrics ,business.industry ,Methylphenidate ,medicine.disease ,United States ,3. Good health ,Clinical trial ,Treatment Outcome ,Clinical Trials, Phase III as Topic ,Clinical Global Impression ,Central Nervous System Stimulants ,medicine.symptom ,business ,lcsh:Medicine (General) ,030217 neurology & neurosurgery ,medicine.drug - Abstract
Alzheimer’s disease (AD) is characterized not only by cognitive and functional decline, but also often by the presence of neuropsychiatric symptoms. Apathy, which can be defined as a lack of motivation, is one of the most prevalent neuropsychiatric symptoms in AD and typically leads to a worse quality of life and greater burden for caregivers. Treatment options for apathy in AD are limited, but studies have examined the use of the amphetamine, methylphenidate. The Apathy in Dementia Methylphenidate Trial (ADMET) found that treatment of apathy in AD with methylphenidate was associated with significant improvement in apathy in two of three outcome measures, some evidence of improvement in global cognition, and minimal adverse events. However, the trial only enrolled 60 participants who were followed for only 6 weeks. A larger, longer-lasting trial is required to confirm these promising findings. The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2) is a phase III, placebo-controlled, masked, 6-month, multi-center, randomized clinical trial targeted to enroll 200 participants with AD and apathy. Participants are randomly assigned 1:1 to 20 mg methylphenidate per day prepared as four over-encapsulated tablets or to matching placebo. The primary outcomes include (1) the mean difference in the Neuropsychiatric Inventory Apathy subscale scores measured as change from baseline to 6 months, and (2) the odds of having a given rating or better on the modified AD Cooperative Study Clinical Global Impression of Change ratings at month 6 compared with the baseline rating. Other outcomes include change in cognition, safety, and cost-effectiveness measured at monthly follow-up visits up to 6 months. Given the prevalence of apathy in AD and its impact on both patients and caregivers, an intervention to alleviate apathy would be of great benefit to society. ADMET 2 follows on the promising results from the original ADMET to evaluate the efficacy of methylphenidate as a treatment for apathy in AD. With a larger sample size and longer follow up, ADMET 2 is poised to confirm or refute the original ADMET findings. ClinicalTrials.gov, NCT02346201 . Registered on 26 January 2015.
- Published
- 2018
- Full Text
- View/download PDF
10. Rural Healthcare Workers' Well-Being: A Systematic Review of Support Interventions.
- Author
-
Malik, Mansoor, Penalosa, Martina, Busch, Isolde Martina, Burhanullah, Haroon, Weston, Christine, Weeks, Kristina, Connors, Cheryl, Michtalik, Henry J., Everly, George, and Wu, Albert W.
- Subjects
- *
RURAL health services , *MEDICAL personnel , *WELL-being , *COVID-19 pandemic , *SOCIAL change - Abstract
Introduction: Although there is increased awareness about healthcare workers' (HCWs') stress and burnout after the COVID-19 pandemic, support interventions should be tailored according to the needs of HCWs. Given the unique challenges rural HCWs face, we sought to systematically identify the types of interventions specifically designed and utilized to support the well-being of HCWs practicing in rural settings. Method: We conducted a comprehensive search of the existing literature through electronic databases to identify quantitative, qualitative, and mixed-methods studies describing supportive interventions for rural HCWs with well-being-related outcomes between January 1, 2023 and March 31, 2023. We used the Effective Public Health Practice Project, Mixed Methods Assessment Tool, and Joanna Briggs Institute Critical Appraisal Checklist to evaluate the study quality. Findings: Out of 1,583 identified records, 25 studies were included in the analysis. The studies described a wide range of supportive interventions and outcomes. The overall quality of the studies was weak to moderate. None of the studies were randomized and only six included controls. Included interventions were generally well- accepted. Quantitative and qualitative themes identified shared decision making, effective supervision, and proactive cultural change as promising interventions that warrant further exploration. Financial interventions alone were not effective. Most of the studies were either unfunded or were funded internally by the institutions. Conclusions: There is limited research in support interventions for rural HCWs. Larger, well-designed studies are needed to explore promising interventions to promote well-being of rural healthcare workforce. Public Significance Statement: This study highlights the needs for more supportive services to the healthcare workers in rural areas. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Mental Health Burden and Burnout in Correctional Workers
- Author
-
Malik, Mansoor, Padder, Samar, Kumari, Suneeta, and Burhanullah, Haroon
- Subjects
Social Science - Abstract
Working in correctional facilities is inherently stressful, and correctional workers have a high rate of anxiety, depression, PTSD, and professional burnout. Correctional workers faced an unprecedented set of challenges during the COVID-19 pandemic, exacerbating an already dire situation. There has been a relative shortage of studies evaluating effective interventions for the psychological consequences of working in correctional facilities. Well-being and mental health Interventions for correctional workers should be embedded in a general framework of support, reducing occupational risk factors, improving mental well-being by developing a positive work environment, improving mental health literacy, and identifying and treating mental health issues. The backbone of the correctional system is its workforce and the mental health and well-being of correctional workers are of paramount importance in an effective correctional system.
- Published
- 2018
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.